Table A2.
Summary of risk scores used in treated hepatitis B virus (HBV) patients
| HCC risk scores | REACH‐B 13 | CU‐HCC 15 | GAG‐HCC 14 | mPAGE‐B 17 |
|---|---|---|---|---|
| n (Cohort) | 3584 | 1005 | 820 | 2001 |
| n (validated) | 1505 | 424 | — | 1000 |
| Place | Taiwan | Hong Kong | Hong Kong | Korea |
| Race | Asian | Asian | Asian | Asian |
| Age (year) | 45.7 | 48 | 40.6 | 50 |
| HBeAg negative (%) | 84.8 | — | 56.6 | 65.8 |
| Cirrhosis (%) | 0 | 38.1 | 15.1 | 19.1 |
| F/U (year) | 12 | 9.94 | 5.62 | 4.1 |
| Antiviral therapy (%) | 0 | 15.1 (during study) | 0 | 100 |
| HCC (%) | 131 (3.7) | 105 (10.4%) | 40 (4.4%) | 132 (6.6%) |
| Parameters | Age, sex, HBV‐DNA, ALT | Age, Alb, HBV‐DNA, cirrhosis, TB | Age, Sex, HBV‐DNA, cirrhosis | Age, Sex, Platelet, Alb |
| Calculator |
Male sex: 2 points Age: 1 point for every 5 years from 35 to 65 years of age (0–6 points) ALT (IU/L): 15–44 (1 point), ≥45 (2 points) Positive HBeAg: 2 points HBV DNA (log copies/mL): 4–5 (3 points), 5–6 (5 points), ≥6 (4 points) |
14 × sex (male = 1; female = 0) + age (in years) + 3 × HBV DNA (log copies/mL) + 33 × cirrhosis (presence = 1; absence = 0) | Age (>50 years = 3; ≤50 = 0) + albumin (≤35 g/L = 20; >35 = 0) + bilirubin (>18 μmol/L = 1.5; <18 = 0) + HBV DNA (<4 log copies/mL = 0; 4–6 = 1; >6 = 4) + cirrhosis (yes = 15; no = 0) | Age (<30 years = 0, 30–39 = 3, 40–49 = 5, 50–59 = 7, 60–69 = 9, ≥70 = 11) + gender (female = 0, male = 2) + Platelets (×109/L) (>250 = 0, 200–250 = 2, 150–200 = 3, 100–150 = 4, <100 = 5) + Albumin (g/dL) (≥4.0 = 0, 3.5–4.0 = 1, 3.0–3.5 = 2, <3.0 = 3) |
| Predictive HCC incidence | ||||
| Risk stratification from score |
0–8: 0–0.8% 9–11: 1.2–3.3% ≥12–17: 5.3–47.4% |
≥101: ~5% |
<5: 0.9% 5–19: 5.5% ≥19: 21.2% |
<9: 0.7% 9–12: 5.1% ≥13: 18.4% |
| AUROC for 5‐year HCC prediction | 0.74 | 0.87 | 0.93 | 0.82 |
ALT, alanine aminotransferase; AUROC, area under the receiver operating characteristic curve; TB, tuberculosis.